Matthew Rotenberg

Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them.

Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them.

Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them.

Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them.

Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them.

Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them.